Disease Overview:Alzheimers Disease-Identifying and Commercializing Market

1
Frontier Pharma Alzheimers Disease-Identifying
and Commercializing Market
2
DESCRIPTION
Large and Innovative Pipeline The active
Alzheimers Disease (AD) pipeline is populated
with 583 products, with a highly diverse range of
molecular targets. GBI Research analysis revealed
a high degree of innovation in this indication,
with 46 of the pipeline being first-in-class
products, acting on over 40 first-in-class
molecular targets. In addition, the pipeline is
characterized by the strong presence of therapies
that target multiple components implicated in the
amyloid cascade, several molecular targets of
which are known to trigger familial AD. Given
that the currently approved therapies for AD are
limited to acetyl cholinesterase inhibitors and
glutamate receptor antagonists, the pipeline
offers a broad range of treatment options that
may possess disease-modifying properties.
However, evaluation of the Preclinical and
clinical evidence for their therapeutic potential
reveals that the novelty of the molecular target
is not sufficient to effectively reduce the rate
of AD progression in human patients.
3
Report Description

• Disease-Modifying Therapies Show Promise in
  Early-Stage Development
• Programs undergoing Preclinical development
  exhibit diverse disease-modifying mechanisms of
  action, and many represent strong alternatives to
  targets with a direct role in the amyloid and tau
  processes due to their roles in promoting
  neuronal survival and plasticity, a process
  critical to memory and cognition. Brain-Derived
  Neurotrophic Factor (BDNF) and Nerve Growth
  Factor (NGF) are considered promising targets in
  AD, primarily due to their potency in exhibiting
  significant neuroprotective effects in
  Preclinical studies. Members of the
  caspase-mediated apoptotic cascade also show
  therapeutic potential, as early investigations
  have revealed an ability to modulate molecular
  mechanisms underlying synaptic plasticity in
  animal models, which translates into amelioration
  of behavioral deficits. Thus, growing insights
  into disease-causing processes in AD are being
  translated into a growing population of
  innovative therapeutic targets, as reflected in
  the highly innovative pipeline.

4
Key Segment

• The merits of novel molecular targets depend
  largely on the body of Preclinical evidence
  underpinning their relevance to AD pathology.
  Many endpoints in Preclinical investigations
  focus on amelioration of amyloid burden and tau
  pathology, as well as cognitive performance in
  animal model systems.
• Based on these assessment criteria, it appears
  that programs targeting the amyloid cascade, tau
  pathology, and the promotion of neuronal survival
  and plasticity all demonstrate promising efficacy
  profiles. Other first-in-class targets that are
  less directly aligned to these three processes
  may not be able to confer disease-modifying
  properties and therefore lack clinical and
  commercial potential.
• Read The Complete Report On http//www.bigmarket
  research.com/frontier-pharma-alzheimers-disease-id
  entifying-and-commercializing-first-in-class-innov
  ation-market

5
Key Market

• Active Deals Landscape with Numerous Investment
  Opportunities
• The AD deals landscape has been highly active
  over the past eight years, with 83 licensing
  agreements and 103 co-development deals. Overall,
  non-first-in-class programs tend to have lower
  valuations than first-in-class programs across
  all stages of drug development, which highlights
  their commercial attractiveness, even in
  early-stage development. Although first-in-class
  programs are associated with greater risk, they
  have more potential to revolutionize or improve
  therapeutic options, meaning that identifying
  promising first-in-class compounds early in
  development offers the greatest potential
  commercial benefit to pharmaceutical companies.
• With 153 first-in-class products that are
  currently in development having not yet been
  involved in a licensing or co-development deal,
  there are numerous opportunities for in-licensing
  or co-development in this indication.

6
SCOPE

• The report covers and includes
• A brief introduction to AD, including symptoms,
  pathophysiology, and overview of pharmacotherapy
  and treatment algorithms
• The changing molecular target landscape between
  market and pipeline and particular focal points
  of innovation in the pipeline
• A comprehensive review of the pipeline for
  first-in-class therapies, analyzed on the basis
  of stage of development, molecule type and
  molecular target
• Identification and assessment of first-in-class
  molecular targets with a particular focus on
  early-stage programs for which clinical utility
  has yet to be evaluated, as well as literature
  reviews of novel molecular targets
• Assessment of the licensing and co-development
  deal landscape for AD therapies and benchmarking
  of deals involving first-in-class versus
  non-first-in-class-products

7
REASONS TO BUY

• The report will assist business development and
  enable marketing executives to strategize their
  product launches, by allowing them to
• Understand the focal shifts in molecular targets
  in the AD pipeline
• Understand the distribution of pipeline programs
  by phase of development, molecule type and
  molecular target
• Access a scientific and clinical analysis of
  first-in-class developmental programs for AD,
  benchmarked against non-first-in-class targets
• Access a list of the first-in-class therapies
  potentially open to deal-making opportunities
• To Get More Details Enquire _at_ http//www.bigmarket
  research.com/report-enquiry/176585

8
Table Of Content

• Executive Summary
• The Case for Innovation
• Clinical and Commercial Landscape
• Clinical and Commercial Landscape
• Assessment of Pipeline Product Innovation
• Liver Cancer Patent Family Analysis
• Signaling Network, Disease Causation and
  Innovation Alignment
• First-in-Class Target Evaluation
• Deals and Strategic Consolidations
• Appendix
• Read The Complete TOC _at_ http//www.bigmarketresear
  ch.com/frontier-pharma-alzheimers-disease-identify
  ing-and-commercializing-first-in-class-innovation-
  market

9
Contact Us
Deep Joshi 5933 NE Win Sivers Drive, 205,
Portland, OR 97220 United States Direct 1
[phone] Toll Free 1 [phone] Fax
1 [phone] Email help_at_bigmarketresearch
.com Web http//www.bigmarketresearch.com